Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?

Joseph Firth, Scott B. Teasdale, Sarah E. Jackson, Davy Vancampfort, Dan Siskind, Jerome Sarris, Marco Solmi

Research output: Contribution to journalArticlepeer-review

Abstract

We read with interest the recent meta-analysis by Goetz and Miller (2018),which reported that circulating levels of ghrelin are significantly reduced by olanzapine treatment. This finding may shed new light on the behavioural and metabolic side-effects of olanzapine, as ghrelin is widely referred to as ‘the hunger hormone’, due to its well-established role in appetite regulation and satiety (Higgins et al., 2007). Somewhat paradoxically, reductions in ghrelin levels are an established risk factor for both binge-eating (Geliebter et al., 2005) and obesity (Tschöp et al., 2001). Indeed, previous research has suggested the drastic weight gain observed in with second-generation antipsychotic treatment may be mediated by increases in appetite (Mayfield et al., 2016). Supporting this, recent population-scale studies have found that individuals with psychotic disorders are not only less active than the general population (Firth et al., 2018b), but also consume substantially more total calories and obesogenic foods (i.e. sugars, carbohydrates, and saturated fats) than people with othermental disorders, even after adjusting for social deprivation and education (Firth et al., 2018a).
Original languageEnglish
Pages (from-to)301-302
Number of pages2
JournalSchizophrenia Research
Volume210
DOIs
Publication statusPublished - 2019

Keywords

  • antipsychotic drugs
  • ghrelin
  • nutrition
  • obesity
  • psychoses

Fingerprint

Dive into the research topics of 'Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?'. Together they form a unique fingerprint.

Cite this